Basic science of epidermolysis bullosa and diagnostic and molecular characterization: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005

International Journal of Dermatology

Volumn 46, Issue 8, 2007, Pages 781-794

  Pfendner, Ellen G ^{a,b,c,d,e,f,g}   Bruckner, Anna ^{a,b,c,d,e,f,g}   Conget, Paulette ^{a,b,c,d,e,f,g}   Mellerio, Jemima ^{a,b,c,d,e,f,g}   Palisson, Francis ^{a,b,c,d,e,f,g}   Lucky, Anne W ^{a,b,c,d,e,f,g}  

^a GENEDX   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DEL DESARROLLO   (Chile)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f Dystrophic Epidermolysis Bullosa Research Association (DebRA) Chile Foundation   (Chile)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; GENE PRODUCT; LENTIVIRUS VECTOR; PROTEIN COL17A1; PROTEIN ITGB4; PROTEIN LAMB3; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

AMNIOCENTESIS; CHILE; CHORION VILLUS; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ECHOGRAPHY; ECTODERMAL DYSPLASIA; EPIDERMOLYSIS BULLOSA; EPIDERMOLYSIS BULLOSA SIMPLEX; FETOSCOPY; FETUS CELL; GENE MUTATION; GENE TRANSFER; HUMAN; INHERITANCE; INTESTINE ATRESIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR GENETICS; MUSCULAR DYSTROPHY; NONHUMAN; NONVIRAL GENE THERAPY; PHENOTYPE; PRENATAL DIAGNOSIS; PROGNOSIS; RECURRENCE RISK; SKIN BIOPSY; SKIN FRAGILITY; SYMPOSIUM; THREE DIMENSIONAL IMAGING; VIRAL GENE THERAPY;

EID: 34547432585     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03307.x     Document Type: Conference Paper

References (147)

1. Fine J-D, Bauer EA, Gedde-Dahl T Jr. Inherited epidermolysis bullosa: definition and historical overview. In: Fine J-D, Bauer EA, McGuire J, et al., eds. Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, MD: The Johns Hopkins University Press, 1999: 1-19.
2. Anton-Lamprecht I, Gedde-Dahl T. Epidermolysis bullosa. In: Rimoin DL, Connor JM, Pyeritz RE, et al., eds. Principles and Practice of Medical Genetics, 4th edn. London: Churchill-Livingstone, 2002: 3810-3897.
3. Fine J-D, Eady RAJ, Bauer EA, et al. Revised classification system for inherited epidermolysis bullosa: Report of the second international consensus meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 2000; 42: 1051-1106.
4. Pulkkinen L, Uitto J. Hemidesmosomal variants of epidermolysis bullosa: mutations in the α6β4 integrin and the 180-kD bullous pemphigoid antigen/type XVII collagen genes. Exp Dermatol 1998; 7: 46-64.
5. Uitto J, Richard G. Progress in epidermolysis bullosa: From eponyms to molecular genetic classification. Clin Dermatol 2005; 23: 33-40.
6. Uitto J, Richard G. Progress in epidermolysis bullosa: Genetic classification and clinical implications. Am J Med Genet 2004; 131C: 61-74.
7. McMillan JR, McGrath JA, Pulkkinen L, et al. Immunohistochemical analysis of the skin in junctional epidermolysis bullosa using laminin 5 chain specific antibodies is of limited value in predicting the underlying gene mutation. Br J Dermatol 1997; 136: 817-822.
8. 4 integrin. J Invest Dermatol 1997; 108: 943-946.
9. Uitto J, Pulkkinen L, Smith FJD, et al. Plectin and human genetic disorders of the skin and muscle. The paradigm of epidermolysis bullosa with muscular dystrophy. Exp Dermatol 1996; 5: 237-246.
10. Corden LD, McLean WH. Human keratin diseases: Hereditary fragility of specific epithelial tissues. Exp Dermatol 1996; 5: 297-307.
11. Irvine AD, McLean WH. Human keratin diseases: The increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 1999; 140: 815-828.
12. Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003; 4: 347-364.
13. Wood P, Baty DU, Lane EB, McLean WH. Long-range polymerase chain reaction for specific full-length amplification of the human keratin 14 gene and novel keratin 14 mutations in epidermolysis bullosa simplex patients. J Invest Dermatol 2003; 120: 495-497.
14. Pfendner EG, Sadowski SG, Uitto J. Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/ genotype correlations, and implications for genetic counseling and prenatal diagnosis. J Invest Dermatol 2005; 125: 239-243.
15. Cassidy AJ, Lane EB, Irvine AD, et al. The Human Intermediate Filament Mutation Database. URL http://www.interfil.org accessed on 03-13-2007
16. Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, et al. A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: Two identical de novo mutations. J Invest Dermatol 2002; 118: 87-93.
17. Charlesworth A, Gagnoux-Palacios L, Bonduelle M, et al. Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. J Invest Dermatol 2003; 121: 1344-1348.
18. Jonkman MF, Pas HH, Nijenhuis M, et al. Deletion of a cytoplasmic domain of integrin beta 4 causes epidermolysis bullosa simplex. J Invest Dermatol 2002; 119: 1275-1281.
19. Huber M, Floeth M, Borradori L, et al. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex. J Invest Dermatol 2002; 118: 185-192.
20. Pasmooij AMG, Van der Steege G, Pas HH, et al. Features of epidermolysis bullosa simplex due to mutations in the ectodomain of type XVII collagen. Br J Dermatol 2004; 13: 125-128.
21. Uttam J, Hutton E, Coulombe PA, et al. The genetic basis of epidermolysis bullosa simplex with mottled pigmentation. Proc Natl Acad Sci USA 1996; 93: 9079-9084.
22. Moog U, de Die-Smulders CE, Scheffer H, et al. Epidermolysis bullosa simplex with mottled pigmentation: Clinical aspects and confirmation of the P24L mutation in the KRT5 gene in further patients. Am J Med Genet 1999; 86: 376-379.
23. Irvine AD, Rugg EL, Lane EB, et al. Molecular confirmation of the unique phenotype of epidermolysis bullosa simplex with mottled pigmentation. Br J Dermatol 2001; 144: 40-45.
24. Irvine AD, McKenna KE, Jenkinson H, Hughes AE. A mutation in the V1 domain of keratin 5 causes epidermolysis bullosa simplex with mottled pigmentation. J Invest Dermatol 1997; 108: 809-810.
25. Hamada T, Ishii N, Kawano Y, et al. The P25L mutation in the KRT5 gene in a Japanese family with epidermolysis bullosa simplex with mottled pigmentation. Br J Dermatol 2004; 150: 609-611.
26. Horiguchi Y, Sawamura D, Mori R, et al. Clinical heterogeneity of 1649delG mutation in the tail domain of keratin 5: A Japanese family with epidermolysis bullosa simplex with mottled pigmentation. J Invest Dermatol 2005; 125: 83-85.
27. Nagao-Watanabe M, Fukao T, Matsui E, et al. Identification of somatic and germline mosaicism for a keratin 5 mutation in epidermolysis bullosa simplex in a family of which the proband was previously regarded as a sporadic case. Clin Genet 2004; 66: 236-238.
28. Nakano A, Chao SC, Pulkkinen L, et al. Laminin 5 mutations in junctional epidermolysis bullosa: Molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum Genet 2002; 110: 41-51.
29. Muhle C, Jiang QJ, Charlesworth A, et al. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease. Hum Genet 2005; 116: 33-42.
30. Posteraro P, De Luca N, Meneguzzi G, et al. Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa. J Invest Dermatol 2004; 123: 639-648.
31. Nakano A, Lestringant GG, Paperna T et al. Junctional epidermolysis bullosa in the Middle East: Clinical and genetic studies in a series of consanguineous families. J Am Acad Dermatol 2002; 46: 510-516.
32. Castiglia D, Posteraro P, Spirito F et al. Novel mutations in the LAMC2 gene in non-Herlitz junctional epidermolysis bullosa: Effects on laminin-5 assembly, secretion, and deposition. J Invest Dermatol 2001; 117: 731-739.
33. Nakano A, Pfendner E, Hashimoto I, et al. Herlitz junctional epidermolysis bullosa. novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermatol 2000; 115: 493-498.
34. Kon A, Pulkkinen L, Hara M et al. Laminin 5 genes and Herlitz junctional epidermolysis bullosa: Novel mutations and polymorphisms in the LAMB3 and LAMC2 genes. Mutations in brief no. 190. Online. Hum Mutat 1998; 12: 288.
35. Varki R, Sadowski S, Pfendner E, et al. Epidermolysis Bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet 2006; 43: 641-652.
36. Pulkkinen L, Uitto J. Heterozygosity for premature termination codon mutations in LAMB3 in siblings with non-lethal junctional epidermolysis bullosa. J Invest Dermatol 1998; 111: 1244-1246.
37. Posteraro P, Sorvillo S, Gagnoux-Palacios L, et al. Compound heterozygosity for an out-of-frame deletion and a splice site mutation in the LAMB3 gene causes nonlethal junctional epidermolysis bullosa. Biochem Biophys Res Commun 1998; 243: 758-764.
38. van Leusden MR, Pas HH, Gedde-Dahl T Jr, et al. Truncated type XVII collagen expression in a patient with non-Herlitz junctional epidermolysis bullosa caused by a homozygous splice-site mutation. Lab Invest 2001; 81: 887-894.
39. Ruzzi L, Pas H, Posteraro P, et al. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol 2001; 116: 182-187.
40. Pulkkinen L, Marinkovich MP, Tran HT, et al. Compound heterozygosity for novel splice site mutations in the BPAG2/COL17A1 gene underlies generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 1999; 113: 1114-1118.
41. McGrath JA, Gatalica B, Christiano AM, et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 1995; 11: 83-86.
42. Gatalica B, Pulkkinen L, Li K, et al. Cloning of the human type XVII collagen gene (COL17A1) and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. Am J Hum Genet 1997; 60: 352-365.
43. Inoue M, Tamai K, Shimizu H, et al. A homozygous missense mutation in the cytoplasmic tail of beta4 integrin, G931D, that disrupts hemidesmosome assembly and underlies non-Herlitz junctional epidermolysis bullosa without pyloric atresia? J Invest Dermatol 2000; 114: 1061-1064.
44. Darling TN, Bauer JW, Hintner H, et al. Generalized atrophic benign epidermolysis bullosa. Adv Dermatol 1997; 13: 87-119.
45. Mellerio JE, Eady RA, Atherton DJ, et al. E210K mutation in the gene encoding the beta3 chain of laminin-5 (LAMB3) is predictive of a phenotype of generalized atrophic benign epidermolysis bullosa. Br J Dermatol 1998; 139: 325-331.
46. Pulkkinen L, Meneguzzi G, McGrath JA, et al. Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J Invest Dermatol 1997; 109: 232-237.
47. Pulkkinen L, McGrath JA, Christiano AM, et al. Detection of sequence variants in the gene encoding the B3 chain of laminin-5 (LAMB3). Hum Mutat 1995; 6: 77-84.
48. McGrath JA, Kivirikko S, Ciatti S, et al. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of Pakistani ancestry: Evidence for a founder effect. J Invest Dermatol 1996; 106: 781-784.
49. Takizawa Y, Pulkkinen L, Chao SC, et al. Mutation report: Complete paternal uniparental isodisomy of chromosome 1: A novel mechanism for Herlitz junctional epidermolysis bullosa. J Invest Dermatol 2000; 115: 307-311.
50. Fassihi H, Wessagowit V, Ashton GH, et al. Complete paternal uniparental isodisomy of chromosome 1 resulting in Herlitz junctional epidermolysis bullosa. Clin Exp Dermatol 2005; 30: 71-74.
51. Pulkkinen L, Bullrich F, Czarnecki P, et al. Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa. Am J Hum Genet 1997; 61: 611-619.
52. Cserhalmi-Friedman PB, Anyane-Yeboa K, Christiano AM. Paternal germline mosaicism in Herlitz junctional epidermolysis bullosa. Exp Dermatol 2002; 11: 468-470.
53. Lepinard C, Descamps P, Meneguzzi G, et al. Prenatal diagnosis of pyloric atresia-junctional epidermolysis bullosa syndrome in a fetus not known to be at risk. Prenat Diagn 2000; 20: 70-75.
54. Gache Y, Romero-Graillet C, Spadafora A, et al. A novel homozygous mutation affecting integrin alpha6 in a case of junctional epidermolysis bullosa with pyloric atresia detected in utero by ultrasound examination. J Invest Dermatol 1998; 111: 914-916.
55. Mellerio JE, Pulkkinen L, McMillan JR, et al. Pyloric atresia-junctional epidermolysis bullosa syndrome: Mutations in the integrin beta4 gene (ITGB4) in two unrelated patients with mild disease. Br J Dermatol 1998; 139: 862-871.
56. Pulkkinen L, Rouan F, Bruckner-Tuderman L, et al. Novel ITGB4 mutations in lethal and non-lethal variants of epidermolysis bullosa with pyloric atresia: Missense vs. nonsense. Am J Hum Genet 1998; 63: 1376-1387.
57. Chavanas S, Gache Y, Vailly J, et al. Splicing modulation of integrin beta4 pre-mRNA carrying a branch point mutation underlies epidermolysis bullosa with pyloric atresia undergoing spontaneous amelioration with ageing. Hum Mol Genet 1999; 8: 2097-2105.
58. Nakano A, Murrell D, Rico J, et al. Epidermolysis bullosa with congenital pyloric atresia: Novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. Pediatr Res 2001; 49: 618-626.
59. Berger TG, Detlefs RL, Donatucci CF. Junctional epidermolysis bullosa, pyloric atresia, and genitourinary disease. Pediatr Dermatol 1986; 3: 130-134.
60. Puvabanditsin S, Garrow E, Samransamraujkit R, et al. Epidermolysis bullosa associated with congenital localized absence of skin, fetal abdominal mass, and pyloric atresia. Pediatr Dermatol 1997; 14: 359-362.
61. Wallerstein R, Klein ML, Genieser N, et al. Epidermolysis bullosa, pyloric atresia, and obstructive uropathy: A report of two case reports with molecular correlation and clinical management. Pediatr Dermatol 2000; 17: 286-289.
62. Kambham N, Tanji N, Seigle RL et al. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. Am J Kidney Dis 2000; 36: 190-196.
63. Ashton GH, Sorelli P, Mellerio JE, et al. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol 2001; 144: 408-414.
64. Pulkkinen L, Kim DU, Uitto J. Epidermolysis bullosa with pyloric atresia: Novel mutations in the β4 integrin gene (ITGB4). Am J Pathol 1998; 152: 157-166.
65. Iacovacci S, Cicuzza S, Odorisio T, et al. Novel and recurrent mutations in the integrin beta 4 subunit gene causing lethal junctional epidermolysis bullosa with pyloric atresia. Exp Dermatol 2003; 12: 716-720.
66. Pulkkinen L, Kurtz K, Xu Y, et al. Genomic organization of the integrin beta 4 gene (ITGB4): A homozygous splice-site mutation in a patient with junctional epidermolysis bullosa associated with pyloric atresia. Lab Invest 1997; 76: 823-833.
67. Pulkkinen L, Kimonis VE, Xu Y, et al. Homozygous beta 4 integrin mutation in junctional epidermolysis bullosa with congenital duodenal atresia. Hum Mol Genet 1997; 6: 669-674.
68. Ruzzi L, Gagnoux-Palacios L, Pinola M, et al. A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia. J Clin Invest 1997; 99: 2826-2831.
69. Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. J Invest Dermatol 2005; 124: 111-115.
70. Nakamura H, Sawamura D, Goto M, et al. Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1). J Mol Diagn 2005; 7: 28-35.
71. McLean WH, Pulkkinen L, Smith FJ, et al. Loss of plectin causes epidermolysis bullosa with muscular dystrophy: CDNA cloning and genomic organization. Genes Dev 1996; 10: 1724-1735.
72. Uitto J, Pulkkinen L, McLean WH. Epidermolysis bullosa: A spectrum of clinical phenotypes explained by molecular heterogeneity. Mol Med Today 1997; 3: 457-465.
73. Schara U, Tucke J, Mortier W, et al. Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. Eur J Pediatr 2004; 163: 218-222.
74. Pfendner E, Rouan F, Uitto J. Progress in epidermolysis bullosa: The phenotypic spectrum of plectin mutations. Exp Dermatol 2005; 14: 241-249.
75. Rezniczek GA, Abrahamsberg C, Fuchs P, et al. Plectin 5′-transcript diversity: Short alternative sequences determine stability of gene products, initiation of translation and subcellular localization of isoforms. Hum Mol Genet 2003; 12: 3181-3194.
76. Varki R, Sadowski S, Uitto J, et al. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype/genotype correlations in the dystrophic subtypes. J Med Genet 2006; September 13 [Epub ahead of print].
77. Mallipeddi R, Bleck O, Mellerio JE, et al. Dilemmas in distinguishing between dominant and recessive forms of dystrophic epidermolysis bullosa. Br J Dermatol 2003; 149: 810-818.
78. Hashimoto I, Kon A, Tamai K, Uitto J. Diagnostic dilemma of 'sporadic' cases of dystrophic epidermolysis bullosa: A new dominant or mitis recessive mutation? Exp Dermatol 1999; 8: 140-142.
79. Whittock NV, Ashton GH, Mohammedi R, et al. Comparative mutation detection screening of the type VII collagen gene (COL7A1) using the protein truncation test, fluorescent chemical cleavage of mismatch, and conformation sensitive gel electrophoresis. J Invest Dermatol 1999; 113: 673-686.
80. Gardella R, Barlati S, Zoppi N et al. -96C→T mutation in the promoter of the collagen type VII gene (COL7A1) abolishing transcription in a patient affected by recessive dystrophic epidermolysis bullosa. Hum Mutat 2000; 16: 275.
81. Salas-Alanis JC, Amaya-Guerra M, McGrath JA. The molecular basis of dystrophic epidermolysis bullosa in Mexico. Int J Dermatol 2000; 39: 436-442.
82. Gardella R, Castiglia D, Posteraro P et al. Genotype-phenotype correlation in Italian patients with dystrophic epidermolysis bullosa. J Invest Dermatol 2002; 119: 1456-1462.
83. Jarvikallio A, Pulkkinen L, Uitto J. Molecular basis of dystrophic epidermolysis bullosa: Mutations in the type VII collagen gene (COL7A1). Hum Mutat 1997; 10: 338-347.
84. Murata T, Masunaga T, Ishiko A, et al. Differences in recurrent COL7A1 mutations in dystrophic epidermolysis bullosa: Ethnic-specific and worldwide recurrent mutations. Arch Dermatol Res 2004; 295: 442-447.
85. Csikos M, Szocs HI, Laszik A, et al. High frequency of the 425A→G splice-site mutation and novel mutations of the COL7A1 gene in central Europe: Significance for future mutation detection strategies in dystrophic epidermolysis bullosa. Br J Dermatol 2005; 152: 879-886.
86. Ashton GH, Mellerio JE, Dunnill MG, et al. Recurrent molecular abnormalities in type VII collagen in southern Italian patients with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 1999; 24: 232-235.
87. Wessagowit V, Ashton GH, Mohammedi R, et al. Three cases of de novo dominant dystrophic epidermolysis bullosa associated with the mutation G2043R in COL7A1. Clin Exp Dermatol 2001; 26: 97-99.
88. Rouan F, Pulkkinen L, Jonkman MF, et al. Novel and de novo glycine substitution mutations in the type VII collagen gene (COL7A1) in dystrophic epidermolysis bullosa: Implications for genetic counseling. J Invest Dermatol 1998; 111: 1210-1213.
89. Lee JY, Li C, Chao SC, et al. A de novo glycine substitution mutation in the collagenous domain of COL7A1 in dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 2000; 292: 159-163.
90. Kon A, McGrath JA, Pulkkinen L, et al. Glycine substitution mutations in the type VII collagen gene (COL7A1) in dystrophic epidermolysis bullosa: implications for genetic counseling. J Invest Dermatol 1997; 108: 224-228
91. Murata T, Masunaga T, Shimizu H, et al. Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 2000; 292: 477-481.
92. Shimizu H, Hammami-Hauasli N, Hatta N, et al. Compound heterozygosity for silent and dominant glycine substitution mutations in COL7A1 leads to a marked transient intracytoplasmic retention of protype VII collagen and a moderately severe dystrophic epidermolysis bullosa phenotype. J Invest Dermatol 1999; 113: 419-421.
93. Nakamura H, Sawamura D, Goto M, et al. The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familial clinical heterogeneity in dominant dystrophic epidermolysis bullosa. J Dermatol Sci 2004; 34: 195-200.
94. Wessagowit V, Kim SC, Woong Oh S, et al. Genotype-phenotype correlation in recessive dystrophic epidermolysis bullosa: When missense doesn't make sense. J Invest Dermatol 2005; 124: 863-866.
95. Sakuntabhai A, Hammami-Hauasli N, Bodemer C, et al. Deletions within COL7A1 exons distant from consensus splice sites alter splicing and produce shortened polypeptides in dominant dystrophic epidermolysis bullosa. Am J Hum Genet 1998; 63: 737-748.
96. Christiano AM, Fine JD, Uitto J. Genetic basis of dominantly inherited transient bullous dermolysis of the newborn: A splice site mutation in the type VII collagen gene. J Invest Dermatol 1997; 109: 811-814.
97. Christiano AM, Anton-Lamprecht I, Amano S, et al. Compound heterozygosity for COL7A1 mutations in twins with dystrophic epidermolysis bullosa: A recessive paternal deletion/insertion mutation and a dominant negative maternal glycine substitution result in a severe phenotype. Am J Hum Genet 1996; 58: 682-693.
98. Cserhalmi-Friedman PB, Garzon MC, Guzman E, et al. Maternal germline mosaicism in dominant dystrophic epidermolysis bullosa. Invest Dermatol 2001; 117: 1327-1328.
99. Wessagowit V, McGrath JA. Clinical and molecular significance of splice site mutations in the Plakophilin 1 gene in patients with ectodermal dysplasia-skin fragility syndrome. Acta Derm Venereol 2005; 85: 386-388.
100. Siegel DH, Ashton GH, Penagos HG, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet 2003; 73: 174-187.
101. Ashton GH, McLean WH, South AP, et al. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. J Invest Dermatol 2004; 122: 78-83.
102. McLean WH, Irvine AD, Hamill KJ, et al. An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngoonychocutaneous syndrome. Hum Mol Genet 2003; 12: 2395-2409.
103. Cheong JE, Wessagowit V, McGrath JA. Molecular abnormalities of the desmosomal protein desmoplakin in human disease. Clin Exp Dermatol 2005; 30: 261-266.
104. Jonkman MF, Pasmooij AM, Pasmans SG, et al. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet 2005; 77: 653-660.
105. Pfendner E, Nakano A, Pulkkinen L, et al. Prenatal diagnosis for epidermolysis bullosa: A study of 144 consecutive pregnancies at risk. Prenat Diagn 2003; 23: 447-456.
106. Rodeck CH, Eady RA, Gosden CM. Prenatal diagnosis of epidermolysis bullosa lethalis. Lancet 1980; 1: 949-952.
107. Fassihi H, Eady RA, Mellerio JE, et al. Prenatal diagnosis for severe inherited skin disorders: 25 years' experience. Br J Dermatol 2006; 154: 106-113.
108. Seubert DE, Feldman B, Krivchenia EL, et al. Molecular and fetal tissue biopsy capabilities are needed to maximize prenatal diagnosis of junctional epidermolysis bullosa: Fetal skin biopsy using a 1-mm microendoscope. Fetal Diagn Ther 2000; 15: 89-92.
109. McGrath JA, Handyside AH. Preimplantation genetic diagnosis of severe inherited skin diseases. Exp Dermatol 1998; 7: 65-72.
110. Cserhalmi-Friedman PB, Tang Y, Adler A, et al. Preimplantation genetic diagnosis in two families at risk for recurrence of Herlitz junctional epidermolysis bullosa. Exp Dermatol 2000; 9: 290-297.
111. Fassihi H, Grace J, Lashwood A et al. Pre-implantation genetic diagnosis of skin fragility-ectodermal dysplasia syndrome. Br J Dermatol 2006; 154: 546-550.
112. Uitto J, Pfendner E, Jackson LG. Probing the fetal genome: Progress in non-invasive prenatal diagnosis. Trends Mol Med 2003; 9: 339-343.
113. Ferrari S, Pellegrini G, Mavilio F, et al. Gene therapy approaches for epidermolysis bullosa. Clin Dermatol 2005; 23: 430-436.
114. Eady RA. Epidermolysis bullosa: Scientific advances and therapeutic challenges. J Dermatol 2001; 28: 638-640.
115. Bauer JW, Laimer M. Gene therapy of epidermolysis bullosa. Expert Opin Biol Ther 2004; 4: 1435-1443.
116. Cao T, Longley MA, Wang XJ, et al. An inducible mouse model for epidermolysis bullosa simplex: Implications for gene therapy. J Cell Biol 2001; 152: 651-656.
117. Capt A, Spirito F, Guaguere E et al. Inherited junctional epidermolysis bullosa in the German pointer: Establishment of a large animal model. J Invest Dermatol 2005; 124: 530-535.
118. Spirito F, Capt A, Del Rio M, et al. Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: Establishment of an immunocompetent animal model for cutaneous gene therapy. Biochem Biophys Res Commun 2006; 339: 769-778.
119. Arin MJ, Roop DR. Inducible mouse models for inherited skin diseases: implications for skin gene therapy. Cells Tissues Organs 2004; 177: 160-168.
120. Jiang QJ, Uitto J. Animal models of epidermolysis bullosa - targets for gene therapy. J Invest Dermatol 2005; 124: Xi-xiii.
121. Lu B, Federoff HJ, Wang Y, et al. Topical application of viral vectors for epidermal gene transfer. J Invest Dermatol 1997; 108: 803-808.
122. Somani AK, Esmail N, Siminovitch KA. Gene therapy and dermatology: More than just skin deep. J Cutan Med Surg 1999; 3: 249-259.
123. Alexeev V, Igoucheva O, Domashenko A, et al. Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol 2000; 18: 43-47.
124. Jiang QJ, Izakovic J, Zenker M, et al. Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents. J Pediatr 2002; 141: 553-559.
125. Baldeschi C, Gache Y, Rattenholl A, et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet 2003; 12: 1897-1905.
126. Chen M, O'Toole EA, Muellenhoff M, et al. Development and characterization of a recombinant truncated type VII collagen 'minigene'. Implication for gene therapy of dystrophic epidermolysis bullosa. J Biol Chem 2000; 275: 24 429-24 435.
127. Dellambra E, Vailly J, Pellegrini G, et al. Corrective transduction of human epidermal stem cells in laminin- 5-dependent junctional epidermolysis bullosa. Hum Gene Ther 1998; 9: 1359-1370.
128. Robbins PB, Lin Q, Goodnough JB, et al. In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci USA 2001; 98: 5193-5198.
129. Woodley DT, Keene DR, Atha T et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 2004; 10: 318-326.
130. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
131. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
132. Ortiz-Urda S, Thyagarajan B, Keene DR, et al. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther 2003; 14: 923-928.
133. Essner JJ, McIvor RS, Hackett PB. Awakening gene therapy with Sleeping Beauty transposons. Curr Opin Pharmacol 2005; 5: 513-519.
134. Ortiz-Urda S, Lin Q, Yant SR, et al. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 2003; 10: 1099-1104.
135. Dallinger G, Puttaraju M, Mitchell LG, et al. Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases. Exp Dermatol 2003; 12: 37-46.
136. Ortiz-Urda S, Thyagarajan B, Keene DR, et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002; 8: 1166-1170.
137. Chen M, Kasahara N, Keene DR, et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 2002; 32: 670-675.
138. Ortiz-Urda S, Lin Q, Green CL, et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003; 111: 251-255.
139. Woodley DT, Krueger GG, Jorgensen CM, et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003; 121: 1021-1028.
140. Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004; 10: 693-695.
141. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; April 17; 98: 1076-1084.
142. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-334.
143. Fathke C, Wilson L, Hutter J, et al. Contribution of bone marrow-derived cells to skin: Collagen deposition and wound repair. Stem Cells 2004; 22: 812-822.
144. Deng W, Han Q, Liao L, et al. Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng 2005; 11: 110-119.
145. De Luca M, Pellegrini G. The importance of epidermal stem cells in keratinocyte-mediated gene therapy. Gene Ther 1997; 4: 381-383.
146. Bickenbach JR, Roop DR. Transduction of a preselected population of human epidermal stem cells: Consequences for gene therapy. Proc Assoc Am Physicians 1999; 111: 184-189.
147. Dellambra E, Pellegrini G, Guerra L, et al. Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa. Hum Gene Ther 2000; 11: 2283-2287.